A New Role for Lateral Flow in Cancer Diagnosis - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A New Role for Lateral Flow in Cancer Diagnosis

  • November 19, 2026

  • 3 min

Share

Clinical Scorecard: A New Role for Lateral Flow in Cancer Diagnosis

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: A New Role for Lateral Flow in Cancer Diagnosis
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPopulation described in the source article.
Care SettingEarly clinical evaluation of a potential portable assay; the source describes testing closer to the patient as a possible future use, and routine diagnostic use has not been established.

Key Highlights

  • A sandwich ELISA using the selected immunoreagents showed a linear sAXL response and a reported limit of detection of 0.16 ng/mL.
  • The lateral flow assay detected higher sAXL concentrations in the PDAC group and statistically differentiated patients from healthy controls.
  • Lateral flow measurements were compared with ELISA findings to provide a reference for quantitative results.
  • The study was small and did not assess discrimination from chronic pancreatitis, benign pancreatic disease, other cancers, or inflammatory conditions.
  • The findings do not establish the assay for screening or as a replacement for imaging, histopathology, cytology, or laboratory ELISA.

Guideline-Based Recommendations

Diagnosis

  • Imaging, tissue sampling, and histopathologic assessment remain central to PDAC diagnosis.
  • The lateral flow sAXL assay is an investigational potential aid and has not been validated for routine diagnosis.

Management

  • Do not treat the assay as a replacement for imaging, histopathology, cytology, or laboratory ELISA.
  • The article does not establish the assay for population screening or definitive primary diagnosis.

Monitoring & Follow-up

  • CA 19-9 analysis is used mainly to support disease monitoring rather than population screening or definitive primary diagnosis.
  • The article does not report a clinical monitoring role for the lateral flow sAXL assay.

Risks

  • The evaluation included only 20 patients with PDAC and 20 healthy controls.
  • Performance against chronic pancreatitis, benign pancreatic disease, other cancers, and inflammatory conditions was not tested.
  • Reference intervals, clinical cutoffs, sensitivity, specificity, and performance across disease stages remain to be established.

Patient & Prescribing Data

Plasma samples from 20 patients with PDAC and 20 healthy controls in a Barcelona-Hospital del Mar cohort.

No treatment was evaluated. The assay is a diagnostic research tool, and the study does not establish clinical prescribing or routine diagnostic use.

Clinical Best Practices

  • Interpret the reported group difference in sAXL in light of the small cohort and healthy-control-only comparison.
  • Do not use the study findings to infer performance in differential diagnosis or screening.
  • Further larger, independent, multicenter studies are needed to establish reference intervals, cutoffs, sensitivity, specificity, and performance across disease stages and relevant differential diagnoses.

Related Resources & Content

Original Source(s)

Related Content